Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study

Affiliation auteursAffiliation ok
TitreResults of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: The UNICANCER SARCOME 11 study
Type de publicationJournal Article
Year of Publication2017
AuteursPautier P., Penel N., Ray-Coquard I., Italiano A., Bompas E., Delcambre C., Bay J-O., Bertucci F., Delaye J., Chevreau C., Cupissol D., L. Le Moal B, Eymard J-C., Thyss A., Isambert N., Guillemet C., Rios M., Piperno-Neumann S., Chenuc G., Duffaud F.
JournalANNALS OF ONCOLOGY
Volume28
Date PublishedSEP
Type of ArticleMeeting Abstract
ISSN0923-7534